Allurion Treats First Commercial Patients in the United States, Marking Major Milestone
Allurion Technologies has successfully treated its first commercial patients in the United States, marking a significant step into the obesity treatment market. The company addresses growing demand from patients discontinuing GLP-1 therapy due to side effects or weight regain.
NATICK, Mass.–(BUSINESS WIRE)–Allurion Technologies, Inc. (OTCID: ALUR), a pioneer in metabolically healthy weight loss, today announced the successful commercial treatment of its first patients in the United States—an inflection point that formally launches the company into the world’s largest and most dynamic obesity market. Allurion is seeing growing demand from patients who have discontinued GLP-1 therapy due to side effects, long-term commitment concerns, or weight regain following disco